Asymptomatic hyperuricemia: is it really asymptomatic?
Yip K, Cohen RE, Pillinger MH.
Curr Opin Rheumatol. 2020 Jan;32(1):71-79. doi: 10.1097/BOR.0000000000000679.
How should we manage asymptomatic hyperuricemia?
Chalès G.
Joint Bone Spine. 2019 Jul;86(4):437-443. doi: 10.1016/j.jbspin.2018.10.004. Epub 2018 Oct 11.
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Waheed Y, Yang F, Sun D.
Korean J Intern Med. 2021 Nov;36(6):1281-1293. doi: 10.3904/kjim.2020.340. Epub 2021 Jul 8.
Asymptomatic hyperuricemia: is it time to intervene?
Paul BJ, Anoopkumar K, Krishnan V.
Clin Rheumatol. 2017 Dec;36(12):2637-2644. doi: 10.1007/s10067-017-3851-y. Epub 2017 Oct 4.
The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.
Wu X, You C.
PeerJ. 2023 Jan 6;11:e14554. doi: 10.7717/peerj.14554. eCollection 2023.
Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB, Neogi T.
Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators.
Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Petreski T, Ekart R, Hojs R, Bevc S.
Ren Fail. 2020 Nov;42(1):978-986. doi: 10.1080/0886022X.2020.1822185.
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P, Chaiyakunapruk N, McKay G, Attia J, Thakkinstian A.
BMC Nephrol. 2022 Jun 23;23(1):223. doi: 10.1186/s12882-022-02850-3.
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.
Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I.
J Adv Res. 2017 Sep;8(5):555-560. doi: 10.1016/j.jare.2017.05.001. Epub 2017 May 5.
